8-K: Recursion's AI Platform Delivers Clinical Proof, Extends Runway

Recursion Pharmaceuticals announced positive clinical validation for its AI-driven platform in FAP, achieved a fifth Sanofi milestone, and extended its cash runway into early 2028.

Summary

• Recursion achieved its first AI-enabled clinical proof of concept with REC-4881 in Familial Adenomatous Polyposis (FAP), demonstrating rapid and durable polyp burden reduction in Phase 2.
• The company reached its fifth program milestone with Sanofi, bringing total payments from the partnership to $134 million to date, with five AI-driven small molecule programs accepted.
• Cash, cash equivalents, and restricted cash stood at $753.9 million as of December 31, 2025, providing an expected cash runway into early 2028 without additional financing.
• Operating cash expense for 2025 was $399.2 million, approximately 10% lower than original guidance, and is projected to be less than $390 million in 2026.
• Total revenue for Q4 2025 increased significantly to $35.5 million from $4.5 million in Q4 2024, driven by a $30 million milestone from Roche and Genentech and increased Sanofi collaboration revenue.
• Net loss for Q4 2025 improved to $(108.1) million from $(178.9) million in Q4 2024, while the full-year 2025 net loss was $(644.8) million, compared to $(463.7) million in 2024.
• The Recursion OS continues to advance, integrating AI across biology, precision design, and clinical development, leading to faster and more efficient drug discovery and development.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, driven by the first clinical validation of its AI platform, significant partnership milestones, and strong financial management extending its cash runway. While full-year net loss increased, the Q4 improvements and future outlook are very encouraging.

Positives

• REC-4881 (MEK1/2) achieved the first clinical validation of the Recursion OS in FAP, showing 43% median reduction in polyp burden after 12 weeks and 53% median reduction maintained after 12 weeks off therapy.
• The company achieved its fifth program milestone with Sanofi, resulting in a $4 million payment and bringing total partnership payments to $134 million.
• Cash, cash equivalents, and restricted cash of $753.9 million as of December 31, 2025, extends the cash runway into early 2028 without additional financing.
• Operating cash expense for 2025 was $399.2 million, 10% below guidance, reflecting disciplined capital allocation and a ~35% year-over-year reduction in pro forma operating expenses.
• Q4 2025 total revenue significantly increased to $35.5 million from $4.5 million in Q4 2024, primarily due to a $30 million milestone from Roche and Genentech.
• Q4 2025 net loss improved to $(108.1) million from $(178.9) million in Q4 2024.
• The Recursion OS has delivered >10 development candidates, synthesizing ~330 compounds per program in ~17 months, significantly faster and more efficiently than industry averages (>2,500 compounds in 42 months).
• Clinical trial operations have improved, with site and country selection reduced from months to hours, 10-40% increase in eligible patient population, and 1.3-1.6 improvement in enrollment rates.

Negatives

• Full-year 2025 net loss increased to $(644.8) million from $(463.7) million in 2024.
• Full-year 2025 research and development expenses increased to $475.3 million from $314.4 million in 2024, driven by Tempus record purchases and acquired IPR&D.
• Full-year 2025 net cash used in operating activities increased to $(371.8) million from $(359.2) million in 2024, primarily due to the inclusion of Exscientia's operations.

Risks

• Challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high.
• Failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors.
• Ability to leverage and enhance the drug discovery platform.
• Ability to obtain financing for development activities and other corporate purposes.
• The success of collaboration activities.
• Ability to obtain regulatory approval of, and ultimately commercialize, drug candidates.
• Ability to obtain, maintain, and enforce intellectual property protections.
• Cyberattacks or other disruptions to technology systems.
• Ability to attract, motivate, and retain key employees and manage growth.
• Inflation and other macroeconomic issues.

Future Outlook

Recursion expects to initiate FDA engagement for REC-4881 in 1H26 to align on a potential registration pathway, with additional clinical data anticipated in 1H27. Early Phase 1 safety and PK data for REC-1245 is expected in 1H26, and for REC-617, REC-3565, and REC-4539 in 1H27 and 2H27 respectively. Go/no-go decisions for Phase 1 initiation of REC-7735 and REC-102 are expected in 2H26. The company anticipates potential for additional near-term milestones from Sanofi programs in the next 12-18 months and expects to translate biological insights from Roche and Genentech maps into early-stage programs across 2026 and beyond. Management projects 2026 operating cash expense to be less than $390 million, excluding partnership inflows and transaction costs, and expects the cash runway to extend into early 2028 without additional financing.

Management Comments

• Najat Khan, Ph.D., CEO & President of Recursion, stated, "Our first AI-enabled clinical proof of concept in FAP and our fifth program milestone achieved with Sanofi reflect the increasing maturity of a deeply integrated model – one that connects biology, chemistry, and clinical development into a continuous learning system."
• Khan also noted, "We enter 2026 with five differentiated clinical programs advancing with defined next-stage milestones, a growing discovery portfolio informed by proprietary platform insights, and more than $500 million in upfront and progress-based milestone payments earned to date."
• Management emphasized, "Pairing bold ambition with disciplined execution, we are building Recursion to compound over time – translating insight into molecules, molecules into medicines, and innovation into measurable impact for patients and shareholders alike."

Industry Context

StockSavvy.ai notes that Recursion's clinical validation of its AI-driven platform in FAP positions it at the forefront of the TechBio sector, demonstrating the tangible impact of AI in drug discovery and development. This achievement aligns with a broader industry trend towards leveraging advanced computational methods to accelerate therapeutic pipelines, particularly for diseases with high unmet needs like FAP. The continued success in partnerships with pharmaceutical giants like Sanofi, Roche, and Genentech further validates the scalability and effectiveness of Recursion's AI Operating System, setting a benchmark for how AI can integrate across the entire drug development lifecycle, from target identification to clinical execution.

Comparison to Industry Standards

• Recursion's platform has delivered advanced candidates by synthesizing approximately 330 compounds per program in about 17 months, significantly outperforming industry averages of over 2,500 compounds and 42 months for similar stages.
• REC-7735 (PI3K H1047R inhibitor) demonstrates >100-fold selectivity for the H1074R mutation over wild-type PI3K, suggesting potential for improved tolerability compared to current pan-PI3K inhibitors like Alpelisib and Capivasertib, which are often limited by metabolic liabilities such as hyperglycemia.
• Preclinical studies showed REC-7735 achieved average tumor regression of -57% in a T47D (PI3K H1047R mutant) CDX model, outperforming Capivasertib (100mg/kg BID) which achieved -11% tumor regression at a higher dose.
• Current PI3K inhibitors (e.g., Alpelisib, PIQRAY) face tolerability-driven limitations, with 14-55% dose reductions, 65-85% experiencing hyperglycemia, and 66-69% dose interruptions, leading to a real-world median time to discontinuation of 3-6 months. REC-7735 aims to address these issues with its precision design.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to positive clinical trial results, successful partnership milestones, extended cash runway, and demonstrated operational efficiency.
• Patients: Significant positive impact for patients, particularly those with Familial Adenomatous Polyposis (FAP), as REC-4881 shows promising efficacy in a disease with no approved pharmacotherapies, offering hope for new treatment options.
• Employees: Continued stability and investment in the platform and pipeline, suggesting ongoing opportunities and a strong company trajectory.
• Partners (Sanofi, Roche, Genentech): Strengthened relationships and potential for further collaboration and milestone payments as programs advance, validating the value of Recursion's AI platform.
• Creditors: Improved financial position and extended cash runway reduce immediate liquidity concerns.

Next Steps

• Initiate FDA engagement in 1H26 to align on a potential registration pathway for REC-4881 (MEK1/2).
• Expand the TUPELO study for REC-4881 to include patients aged 18+ and continue dose optimization efforts.
• Expect additional Phase 1b/2 clinical data for REC-4881 in 1H27.
• Expect early Phase 1 safety and PK monotherapy data for REC-1245 (RBM39) in 1H26.
• Expect early Phase 1 safety and PK combination data for REC-617 (CDK7) in 1H27.
• Expect early Phase 1 safety and PK monotherapy data for REC-3565 (MALT1) in 1H27.
• Expect early Phase 1 safety and PK monotherapy data for REC-4539 (LSD1) in 2H27.
• Anticipate data-driven go/no-go decisions on Phase 1 initiation for REC-7735 (PI3K H1047R) and REC-102 (ENPP1) in 2H26.
• Advance Sanofi programs towards potential lead series and development candidate designation milestones in the next 12-18 months.
• Translate biological insights from maps delivered to Roche and Genentech to early-stage programs across 2026 and beyond.

Key Dates

Recommendation

The filing presents compelling evidence of Recursion's progress, highlighted by the first clinical validation of its AI-driven platform in FAP, which is a significant de-risking event for a clinical-stage company. The continued achievement of milestones with major pharmaceutical partners like Sanofi, Roche, and Genentech validates the commercial viability and scientific rigor of its technology. Furthermore, the company's disciplined capital management, evidenced by exceeding cost-saving targets and extending its cash runway into early 2028 without additional financing, provides a strong financial foundation. These factors collectively suggest a robust growth trajectory and significant upside potential for the stock, making it a strong buy for seasoned investors.

Keywords

TechBio, AI drug discovery, clinical stage, FAP, MEK1/2, Sanofi, Roche, Genentech, oncology, immunology, rare disease, neuroscience, PI3K, CDK7, RBM39, MALT1, LSD1, ENPP1, pharmaceuticals, biotechnology, drug development, financial results, cash runway